Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
We measured anti-Xa activity before and at 2, 4, 9 and 12 h after subcutaneous injection of 0.3 ml nadroparin (2850 IU anti-Xa) in normal-weight volunteers (median bodyweight 71 kg, n=5) and compared them to the anti-Xa activity after subcutaneous injection of 0.6 ml nadroparin (5700 IU anti-Xa) in obese patients (median bodyweight 134 kg, n=8). The resulting median anti-Xa activity after 4 h was 1.4 times greater in the group of obese patients. This finding suggests that a linear, weight-adjusted increase in the prophylactic dose of nadroparin does not result in a linear increase of anti-Xa activity in obese patients.
Heizmann
Marc
M
Division of Hematology, Department of Internal Medicine, Kantonsspital, CH-6000 Lucerne 16, Switzerland.
Baerlocher
Gabriela M
GM
Steinmann
Felix
F
Horber
Fritz F
FF
Wuillemin
Walter
W
D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D019540:Area Under Curve; D001835:Body Weight; D002863:Chromogenic Compounds; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D015951:Factor Xa / Q000032:analysis / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D017762:Nadroparin / Q000008:administration & dosage* / Q000494:pharmacology; D009765:Obesity; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D002863:Chromogenic Compounds; D017762:Nadroparin; D015951:Factor Xa